Circ_0049271 targets the miR-1197/PTRF axis to attenuate the malignancy of osteosarcoma.

Publisher: IOS Press Country of Publication: Netherlands NLM ID: 101256509 Publication Model: Print Cited Medium: Internet ISSN: 1875-8592 (Electronic) Linking ISSN: 15740153 NLM ISO Abbreviation: Cancer Biomark Subsets: MEDLINE

Original Publication: Amsterdam ; Washington, DC : IOS Press, c2005-

Osteosarcoma*/genetics ; Osteosarcoma*/pathology ; Osteosarcoma*/metabolism ; MicroRNAs*/genetics ; MicroRNAs*/metabolism ; RNA, Circular*/genetics ; Cell Proliferation* ; Bone Neoplasms*/genetics ; Bone Neoplasms*/pathology ; Bone Neoplasms*/metabolism; Humans ; Animals ; Mice ; Cell Line, Tumor ; Gene Expression Regulation, Neoplastic ; RNA-Binding Proteins/genetics ; RNA-Binding Proteins/metabolism ; Cell Movement/genetics

Background: Circular RNAs (circRNAs) perform key regulatory functions in osteosarcoma (OS) tumorigenesis. In this study, we aimed to explore the detailed action mechanisms of circ_0049271 in OS progression.
Methods: Cell colony formation, cell counting kit-8, and transwell assays were performed to assess the proliferation and invasion of OS cells. Quantitative reverse transcription-polymerase chain reaction and western blotting were used to determine the expression levels of polymerase 1 and transcript release factor (PTRF), microRNA (miR)-1197, and circ_0049271 in OS cells. Furthermore, RNA immunoprecipitation and dual luciferase assays were conducted to explore the targeted relationships among PTRF, miR-1197, and circ_0049271. Finally, a tumor formation assay was conducted to determine the effects of circ_0049271 on in vivo tumor growth in mice.
Results: High expression levels of miR-1197 and low levels of circ_0049271 and PTRF were observed in OS cells. circ _0049271 targeted miR-1197 to mediate PTRF expression. Moreover, the proliferation and invasion of OS cells were repressed by circ_0049271 or PTRF overexpression and increased by miR-1197 upregulation. Enforced circ_0049271 also impeded tumor growth in vivo. Upregulation of miR-1197 reversed the antitumor effects of circ_0049271 on OS progression in vitro; however, PTRF overexpression attenuated the cancer-promoting effects of miR-1197 on OS in vitro.
Conclusions: Our findings revealed that circ_0049271 targeted the miR-1197/PTRF axis to attenuate the malignancy of OS, suggesting a potential target for its clinical treatment.

Cell Prolif. 2021 Jan;54(1):e12936. (PMID: 33103338)
Biomed Pharmacother. 2019 Sep;117:109041. (PMID: 31181445)
Ann Oncol. 2010 Oct;21 Suppl 7:vii320-5. (PMID: 20943636)
Front Genet. 2021 May 17;12:632359. (PMID: 34079579)
Cell Cycle. 2021 Oct;20(20):2125-2136. (PMID: 34570663)
Cancer Manag Res. 2020 Sep 11;12:8287-8302. (PMID: 32982424)
Cell Physiol Biochem. 2018;45(6):2506-2515. (PMID: 29554650)
Mayo Clin Proc. 2012 May;87(5):475-87. (PMID: 22560526)
J Cell Mol Med. 2021 Jan;25(1):510-520. (PMID: 33264494)
Oncogene. 2014 May 22;33(21):2728-36. (PMID: 23770857)
Thorac Cancer. 2022 Jan;13(1):61-75. (PMID: 34806315)
EMBO J. 1998 May 15;17(10):2855-64. (PMID: 9582279)
JAAPA. 2018 Aug;31(8):15-19. (PMID: 29979330)
BMC Cancer. 2021 Jul 23;21(1):849. (PMID: 34301211)
J Clin Oncol. 2015 Sep 20;33(27):3029-35. (PMID: 26304877)
Aging (Albany NY). 2021 Feb 22;13(4):6091-6102. (PMID: 33617480)
J Cell Biochem. 2012 Jan;113(1):322-8. (PMID: 21913217)
Cell Oncol (Dordr). 2016 Oct;39(5):463-471. (PMID: 27376839)
Mol Cancer. 2019 Mar 30;18(1):56. (PMID: 30925885)
Cancer Control. 2008 Jan;15(1):13-20. (PMID: 18094657)
J Exp Clin Cancer Res. 2021 Jul 16;40(1):235. (PMID: 34271943)
J Cell Mol Med. 2019 Oct;23(10):6720-6729. (PMID: 31448882)
FEBS Open Bio. 2020 Jul;10(7):1251-1260. (PMID: 32348630)
J Oncol. 2021 Sep 10;2021:5193913. (PMID: 34539783)
Life Sci. 2020 Feb 15;243:117254. (PMID: 31917993)
Am J Med Sci. 2021 Jan;361(1):98-105. (PMID: 32962802)
J Bone Oncol. 2021 Apr 22;28:100360. (PMID: 33996428)
Adv Exp Med Biol. 2018;1087:67-79. (PMID: 30259358)
Cancer Gene Ther. 2021 Jun;28(6):619-633. (PMID: 33139818)
Cancer Lett. 2017 Feb 1;386:196-207. (PMID: 27894957)
Cancer Cell Int. 2020 Feb 10;20:48. (PMID: 32063749)
Nat Rev Cancer. 2018 Jan;18(1):5-18. (PMID: 29170536)
Cell. 2008 Jan 11;132(1):113-24. (PMID: 18191225)
Acta Biochim Biophys Sin (Shanghai). 2020 Jun 20;52(6):631-637. (PMID: 32409840)
Cancer Biol Ther. 2020;21(3):231-240. (PMID: 31718519)
Cancer Manag Res. 2021 Jan 29;13:861-870. (PMID: 33542659)
Am J Cancer Res. 2015 Jan 15;5(2):472-80. (PMID: 25973291)
Am Fam Physician. 2018 Aug 15;98(4):205-213. (PMID: 30215968)
Mol Oncol. 2017 Aug;11(8):1050-1064. (PMID: 28486750)
Bioengineered. 2021 Dec;12(1):5620-5631. (PMID: 34515615)
Oncol Rep. 2016 Nov;36(5):2609-2618. (PMID: 27634346)
Cancer. 1999 Oct 15;86(8):1602-8. (PMID: 10526292)
Int J Oncol. 2020 May;56(5):1055-1063. (PMID: 32319566)
Neuro Oncol. 2021 Mar 25;23(3):387-399. (PMID: 33140095)
Tohoku J Exp Med. 2021;254(3):189-197. (PMID: 34305100)
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820943217. (PMID: 33153390)
Aging (Albany NY). 2021 Dec 14;13(23):25484-25495. (PMID: 34905503)
Cancer Treat Res. 2009;152:3-13. (PMID: 20213383)
Biosci Rep. 2019 May 17;39(5):. (PMID: 31036604)
Nat Rev Mol Cell Biol. 2013 Feb;14(2):98-112. (PMID: 23340574)
J Cell Mol Med. 2020 Feb;24(3):2202-2214. (PMID: 31923350)

Keywords: Osteosarcoma; PTRF; circRNA; circ_0049271; miR-1197

0 (MicroRNAs)
0 (RNA, Circular)
0 (MIRN1247 microRNA, human)
0 (RNA-Binding Proteins)

Date Created: 20240405 Date Completed: 20240629 Latest Revision: 20240816

20240816

PMC11321495

10.3233/CBM-230191

38578882